Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Inclusion Criteria

• HLA-A*02:01 positive
• MAGE-A4 positive tumor
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
• Selected advanced solid tumors
• Relapsed from, refractory to, or intolerant of standard therapy
• Measurable disease per RECIST v1.1 (expansion)
• If applicable, must agree to use highly effective contraception

Exclusion Criteria

• Symptomatic or untreated central nervous system metastasis
• Inadequate washout from prior anticancer therapy
• Significant ongoing toxicity from prior anticancer treatment
• Impaired baseline organ function as evaluated by out-of-range laboratory values
• Clinically significant cardiac disease
• Active infection requiring systemic antibiotic therapy
• Known history of human immunodeficiency virus (HIV)
• Active hepatitis B virus (HBV) or hepatitis C virus (HCV)
• Ongoing treatment with systemic steroids or other immunosuppressive therapies
• Significant secondary malignancy
• Pregnancy or lactation